John Zalcberg

31.7k total citations · 9 hit papers
410 papers, 18.5k citations indexed

About

John Zalcberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, John Zalcberg has authored 410 papers receiving a total of 18.5k indexed citations (citations by other indexed papers that have themselves been cited), including 239 papers in Oncology, 160 papers in Pulmonary and Respiratory Medicine and 80 papers in Surgery. Recurrent topics in John Zalcberg's work include Colorectal Cancer Treatments and Studies (118 papers), Gastric Cancer Management and Outcomes (101 papers) and Gastrointestinal Tumor Research and Treatment (54 papers). John Zalcberg is often cited by papers focused on Colorectal Cancer Treatments and Studies (118 papers), Gastric Cancer Management and Outcomes (101 papers) and Gastrointestinal Tumor Research and Treatment (54 papers). John Zalcberg collaborates with scholars based in Australia, United States and United Kingdom. John Zalcberg's co-authors include R. J. Simes, Val Gebski, Bryan Burmeister, Christos S. Karapetis, Derek J. Jonker, Niall C. Tebbutt, B. Mark Smithers, Dongsheng Tu, Chris J. O’Callaghan and Timothy Price and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

John Zalcberg

388 papers receiving 18.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

2008 2.8k citations Christos S. Karapetis, Derek J. Jonker et al. profile →
Cetuximab for the Treatment of Colorectal Cancer

2007 1.4k citations Derek J. Jonker, Chris J. O’Callaghan et al. profile →
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

2004 1.3k citations John Zalcberg, Jean‐Yves Blay et al. profile →
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

2011 1.2k citations Katrin Marie Sjoquist, B. Mark Smithers et al. profile →
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis

2007 912 citations Val Gebski, B. Mark Smithers et al. profile →
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

2006 654 citations Jean‐Yves Blay, John Zalcberg et al. profile →
Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04

2012 585 citations Stephen P. Ackland, Trevor Leong et al. Journal of Clinical Oncology profile →
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

2010 573 citations Derek J. Jonker, Dongsheng Tu et al. profile →
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

2020 251 citations Jean‐Yves Blay, Michael C. Heinrich et al. profile →

Peers

Countries citing papers authored by John Zalcberg

Since Specialization

Citations

This map shows the geographic impact of John Zalcberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Zalcberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Zalcberg more than expected).

Fields of papers citing papers by John Zalcberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Zalcberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Zalcberg. The network helps show where John Zalcberg may publish in the future.

Co-authorship network of co-authors of John Zalcberg

This figure shows the co-authorship network connecting the top 25 collaborators of John Zalcberg. A scholar is included among the top collaborators of John Zalcberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Zalcberg. John Zalcberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disparities in Timeliness and Guideline‐Concordant Treatment is Associated With Excess Mortality in Public Versus Private Lung Cancer Patients 2025 ·Asia-Pacific Journal of Clinical Oncology ·Jonathan Pham, Tiffany Lin, Eldho Paul, (unknown), (unknown), Matthew Conron, Gavin Wright, (unknown), Gary Richardson, Phillip Antippa, (unknown), Susan Harden, John Zalcberg, Rob G. Stirling	0
2	LBA58 A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG 2024 ·Annals of Oncology ·Trevor Leong, B. Mark Smithers, (unknown), Karin Haustermans, (unknown), Val Gebski, P. R. O’Connell, John Zalcberg, Alex Boussioutas, Michael Findlay, David J. Willis, Angela Moore, Florian Lordick, Claire O’Callaghan, (unknown), Gail Darling, A. H. Strickland, (unknown), Laurent Mineur, John Simes	1
3	Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials 2024 ·Clinical Cancer Research ·(unknown), (unknown), Emma Titmuss, Dongsheng Tu, Stephanie Yasmin Brule, Rachel Goodwin, Derek J. Jonker, Timothy Price, John Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Lillian L. Siu, Jeremy Shapiro, John Simes, Sharlene Gill, Chris J. O’Callaghan, Jonathan M. Loree	3
4	The impact of delayed diagnosis and treatment due to COVID-19 on Australian thyroid cancer patients: a qualitative interview study 2024 ·BMJ Open ·(unknown), Anthony Glover, (unknown), Benjamin Brown, Rachael H Dodd, James C. Lee, Jeremy Millar, (unknown), John Zalcberg, Jonathan W. Serpell, Liane Ioannou, Brooke Nickel	2
5	A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer 2024 ·Heliyon ·(unknown), (unknown), Robert G. Ramsay, Catherine Mitchell, Shienny Sampurno, Toàn Pham, Joseph C. Kong, Stephen Q. Wong, Alexander G. Heriot, Sanjeev Deva, Matthew Burge, (unknown), Anne‐Sophie W. Møller, Łukasz Kuryk, Jon Amund Eriksen, Magnus Jäderberg, John Zalcberg, Michael Michael	2
6	Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS) 2023 ·Cancers ·(unknown), Erica T. Warner, John Zalcberg, Andrew Haydon, Galina Polekhina, G. J. van Londen, Peter Gibbs, Wendy B. Bernstein, Jeanne Tie, Jeremy Millar, Victoria Mar, John J. McNeil, Robyn L. Woods, Suzanne G. Orchard	4
7	Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals 2022 ·Cancer Prevention Research ·Andrew Bakshi, Yin Cao, Suzanne G. Orchard, Prudence R. Carr, Amit D. Joshi, Alisa K. Manning, Daniel D. Buchanan, Asad Umar, Ingrid Winship, Peter Gibbs, John Zalcberg, Finlay Macrae, John J. McNeil, Paul Lacaze, Andrew T. Chan	3
8	The SYMPTOM‐upper gastrointestinal study: A mixed methods study exploring symptom appraisal and help‐seeking in Australian upper gastrointestinal cancer patients 2022 ·European Journal of Cancer Care ·(unknown), Shakira Milton, (unknown), (unknown), (unknown), Fiona M Walter, John Zalcberg, Jon Emery	3
9	Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial 2022 ·Journal of Clinical Oncology ·Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, (unknown), Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich	61
10	Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology 2022 ·Current Oncology Reports ·(unknown), John Zalcberg, G. J. van Londen, Erica T. Warner, Prudence R. Carr, Andrew Haydon, Suzanne G. Orchard	23
11	Functional Decline in the Cancer Patient: A Review 2022 ·Cancers ·(unknown), Suzanne G. Orchard, Erica T. Warner, G. J. van Londen, John Zalcberg	58
12	Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards 2021 ·The Medical Journal of Australia ·Eva Segelov, (unknown), Sanchia Aranda, David C. Currow, John Zalcberg, Alexander G. Heriot, Linda Mileshkin, John Coutsouvelis, Jeremy Millar, Brian T. Collopy, Jon Emery, (unknown), (unknown), (unknown), Janet Wale, Stephen Hancock, (unknown), John Bashford	3
13	Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial 2020 ·Clinical Cancer Research ·Jonathan M. Loree, (unknown), Dongsheng Tu, Derek J. Jonker, Daniel L. Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Chris J. O’Callaghan, Paul Waring, Hagen F. Kennecke, Stanley R. Hamilton, Scott Kopetz	19
14	Barriers and enablers to the implementation of multidisciplinary team meetings: a qualitative study using the theoretical domains framework 2020 ·BMJ Quality & Safety ·Ashika Maharaj, Sue Evans, John Zalcberg, Liane Ioannou, Marnie Graco, Daniel Croagh, Charles Pilgrim, (unknown), David Goldstein, Jennifer Philip, James G. Kench, Neil D. Merrett, Rachel Ε. Neale, Kate White, Peter Evans, Trevor Leong, Sally Green	16
15	Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework 2020 ·PLoS ONE ·Ashika Maharaj, Sue Evans, John Zalcberg, Liane Ioannou, Marnie Graco, Daniel Croagh, Charles Pilgrim, (unknown), David Goldstein, Jennifer Philip, James G. Kench, Neil D. Merrett, Rachel Ε. Neale, Kate White, Peter Evans, Trevor Leong, Sally Green	3
16	Clearing the air: towards agreement about access to high cost cancer medicines 2018 ·Annals of Oncology ·Wendy Lipworth, Ian Kerridge, Narcyz Ghinea, John Zalcberg	2
17	Advances in Molecular Pathology and Treatment of Periampullary Cancers 2015 ·Pancreas ·Manju D. Chandrasegaram, John W. Chen, Timothy Price, John Zalcberg, Katrin Marie Sjoquist, Neil D. Merrett	20
18	PROGNOSTIC VALUE OF EARLY OBJECTIVE TUMOR RESPONSE (EOTR) TO FIRST LINE SYSTEMIC THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS OF RANDOMIZED TRIALS FROM THE ARCAD DATABASE 2013 ·Asia-Pacific Journal of Clinical Oncology ·Dirkje W. Sommeijer, Qian Shi, (unknown), Katrin Marie Sjoquist, (unknown), Michel Seymour, Jim Cassidy, Richard M. Goldberg, Jean‐Yves Douillard, J. Randolph Hecht, Herbert I. Hurwitz, Christophe Tournigand, Niall C. Tebbutt, Enrique Aranda, John Souglakos, Fairooz F. Kabbinavar, Benoist Chibaudel, Aimery de Gramont, Daniel J. Sargent, John Zalcberg	2
19	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study 2010 ·Journal of Clinical Oncology ·Niall C. Tebbutt, Kate Wilson, Val Gebski, Michelle M. Cummins, Diana Zannino, Guy A. Van Hazel, Bridget A. Robinson, A. Broad, Vinod Ganju, Stephen P. Ackland, Garry Forgeson, David Cunningham, Mark Saunders, Martin R. Stockler, (unknown), John Zalcberg, R. J. Simes, Timothy Price	315
20	An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin 2005 ·Cancer Research ·Richard W. Tothill, Adam Kowalczyk, Danny Rischin, (unknown), Izhak Haviv, Ryan K. van Laar, Paul Waring, John Zalcberg, Robyn L. Ward, Andrew V. Biankin, Robert L. Sutherland, Susan M. Henshall, Kwun M. Fong, Jonathan R. Pollack, David D.L. Bowtell, Andrew Holloway	153

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact